Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include evogliptina and evogliptine. Its PubChem CID is 25022354.
Evogliptin
| CAS No | 1222102-29-5 |
|---|---|
| Molecular Formula | C19H26F3N3O3 |
| Molecular Weight | 401.4 g/mol |
| Synonyms | (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
The listed CAS number is 1222102-29-5.
The listed molecular formula is C19H26F3N3O3.
The listed molecular weight is 401.4 g/mol.
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one.
The source lists evogliptina and evogliptine.